{"id":"mr4","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T18:13:40.286763","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without access to detailed clinical trial data or published mechanisms, the precise molecular target and pharmacological action of MR4 cannot be reliably determined. Astellas has not released comprehensive mechanistic information for this Phase 3 candidate in the public domain.","oneSentence":"MR4 is an investigational compound in development by Astellas Pharma, but its specific mechanism of action is not publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:14.326Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["pubmed(419)"],"trialDetails":[{"nctId":"NCT01294020","phase":"PHASE2","title":"Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-05-25","conditions":"Intestine Transplantation, Kidney Transplantation, Lung Transplantation","enrollment":81},{"nctId":"NCT04666259","phase":"PHASE3","title":"Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-25","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":56},{"nctId":"NCT02917720","phase":"PHASE2","title":"2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"European LeukemiaNet","startDate":"2016-09","conditions":"Chronic Myeloid Leukemia","enrollment":75},{"nctId":"NCT01784068","phase":"PHASE2","title":"Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-19","conditions":"Chronic Myelogenous Leukemia","enrollment":215},{"nctId":"NCT01698905","phase":"PHASE2","title":"Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-20","conditions":"Chronic Myeloid Leukemia","enrollment":163},{"nctId":"NCT06409936","phase":"PHASE2","title":"PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML","status":"RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2025-06-26","conditions":"CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive","enrollment":160},{"nctId":"NCT06888739","phase":"","title":"Development and Validation of Interpretable Machine Learning Models Incorporating Paraspinal Muscle Quality for to Predict Cage Subsidence Risk Followingposterior Lumbar Interbody Fusion","status":"COMPLETED","sponsor":"Hao Liu","startDate":"2025-03-01","conditions":"Degenerative Lumbar Diseases, Cage, Machine Learning","enrollment":720},{"nctId":"NCT02118896","phase":"PHASE3","title":"Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2003-02-24","conditions":"Heart Transplantation, Liver Transplantation, Kidney Transplantation","enrollment":850},{"nctId":"NCT01011205","phase":"PHASE3","title":"Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09-30","conditions":"Liver Transplantation","enrollment":893},{"nctId":"NCT00717470","phase":"PHASE4","title":"A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-05-14","conditions":"Kidney Transplantation","enrollment":1252},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT01614665","phase":"PHASE2","title":"A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-04-03","conditions":"Heart Transplantation, Kidney Transplantation, Liver Transplantation","enrollment":44},{"nctId":"NCT05096936","phase":"NA","title":"Pilates Method and/or Photobiomodulation in Women With Stress Urinary Incontinence","status":"COMPLETED","sponsor":"Universidade de Caxias do Sul","startDate":"2021-10-14","conditions":"Laser Therapy, Urinary Incontinence,Stress, Pilates Method","enrollment":33},{"nctId":"NCT03117816","phase":"PHASE3","title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2017-05-04","conditions":"Chronic Myeloid Leukemia in Remission","enrollment":214},{"nctId":"NCT02269267","phase":"PHASE2","title":"The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2014-12-18","conditions":"Leukemia, Myeloid, Chronic","enrollment":173},{"nctId":"NCT04934709","phase":"NA","title":"Photobiomodulation Therapy Combined With Static Magnetic Field on the Subsequent Performance","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2015-05","conditions":"Skeletal Muscle Performance","enrollment":12},{"nctId":"NCT02236988","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-01-07","conditions":"Healthy Volunteers","enrollment":80},{"nctId":"NCT03089424","phase":"NA","title":"Photobiomodulation Therapy on Low Back Pain","status":"COMPLETED","sponsor":"Universidade Cidade de Sao Paulo","startDate":"2017-04-06","conditions":"Low Back Pain","enrollment":148},{"nctId":"NCT03895671","phase":"PHASE2","title":"PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS","status":"UNKNOWN","sponsor":"Versailles Hospital","startDate":"2019-06-19","conditions":"CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS","enrollment":40},{"nctId":"NCT02174445","phase":"PHASE3","title":"An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years","status":"TERMINATED","sponsor":"Prof. Dr. Nikolas von Bubnoff","startDate":"2014-03","conditions":"Chronic Myeloid Leukemia","enrollment":14},{"nctId":"NCT04043676","phase":"PHASE2","title":"Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia","status":"UNKNOWN","sponsor":"Fundación Teófilo Hernando, Spain","startDate":"2019-04-30","conditions":"Chronic Myeloid Leukemia","enrollment":40},{"nctId":"NCT03859505","phase":"NA","title":"Photobiomodulation Therapy on Inflammatory Mediators on Low Back Pain","status":"COMPLETED","sponsor":"Universidade Cidade de Sao Paulo","startDate":"2019-03-18","conditions":"Low Back Pain","enrollment":18},{"nctId":"NCT03751332","phase":"PHASE4","title":"The Vienna Prograf and Endothelial Progenitor Cell Extension Study","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2008-03","conditions":"Immunosuppression, Renal Failure","enrollment":87},{"nctId":"NCT03653299","phase":"NA","title":"Effects of Phototherapy on Gait and Balance of Post-stroke Individuals","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2016-06-13","conditions":"Post-stroke in Association to Phototherapy","enrollment":10},{"nctId":"NCT03573596","phase":"PHASE2","title":"Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2018-02-01","conditions":"CML, Relapsed","enrollment":134},{"nctId":"NCT03566186","phase":"NA","title":"Effects of Phototherapy Associated With Sprint and Squat Training on Cardiac Autonomic Modulation","status":"COMPLETED","sponsor":"Paulista University","startDate":"2017-09-03","conditions":"Phototherapy, Autonomic Nervous System, Training","enrollment":39},{"nctId":"NCT01332513","phase":"PHASE1","title":"An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-10","conditions":"Epilepsy","enrollment":36},{"nctId":"NCT02715050","phase":"NA","title":"Phototherapy Applied in Association With Muscular Training","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2016-03","conditions":"Muscle Adaptation","enrollment":48},{"nctId":"NCT02918916","phase":"NA","title":"Phototherapy Applied During Combined Training","status":"UNKNOWN","sponsor":"São Paulo State University","startDate":"2017-01","conditions":"Healthy Volunteers","enrollment":45},{"nctId":"NCT00420043","phase":"PHASE1","title":"Effect of Food on Bioavailability of Modified Release Formulations of Imatinib","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-09","conditions":"Healthy","enrollment":32},{"nctId":"NCT00459719","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-03","conditions":"Liver Transplantation","enrollment":42},{"nctId":"NCT00619398","phase":"PHASE3","title":"A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-01","conditions":"Liver Transplantation","enrollment":172},{"nctId":"NCT00481819","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":240},{"nctId":"NCT02474602","phase":"NA","title":"Phototherapy Applied in Association With Strength Training","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2014-06","conditions":"Muscle Development in Association to Phototherapy","enrollment":48},{"nctId":"NCT02588768","phase":"NA","title":"Photobiomodulation Therapy in a Field Test With High-level Rugby Players","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2015-02","conditions":"High-level Rugby Athletes, Performance, Recovery","enrollment":12},{"nctId":"NCT01018914","phase":"PHASE4","title":"A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04","conditions":"Liver Transplantation","enrollment":44},{"nctId":"NCT00717678","phase":"PHASE3","title":"A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-12","conditions":"Kidney Transplantation, Transplantation Immunology, Host vs Graft Reaction","enrollment":73},{"nctId":"NCT01332201","phase":"PHASE2","title":"Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-07","conditions":"Heart Transplantation, Lung Transplantation, Pancreas (Including SPK) Transplantation","enrollment":17},{"nctId":"NCT01435291","phase":"PHASE4","title":"AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2011-10","conditions":"Renal Transplantation","enrollment":45},{"nctId":"NCT00865137","phase":"PHASE3","title":"An Open Study Assessing Bioavailability of a Modified Formulation of Tacrolimus in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-09","conditions":"Kidney Transplantation","enrollment":27},{"nctId":"NCT00481481","phase":"PHASE3","title":"Conversion Study From Cyclosporine to FK506MR Based Immunosuppression in Kidney Transplant Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-04","conditions":"Transplantation","enrollment":346},{"nctId":"NCT00384202","phase":"PHASE3","title":"A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-10","conditions":"Transplantation","enrollment":112},{"nctId":"NCT00189839","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-08","conditions":"Kidney Transplantation","enrollment":699},{"nctId":"NCT00818194","phase":"PHASE1","title":"Comparison of Extended Release Tacrolimus (Advagraf) and Cyclosporine A Microemulsion on Renal Function in Healthy Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04","conditions":"Healthy","enrollment":18},{"nctId":"NCT00189826","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Liver Transplantation.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-08","conditions":"Liver Transplantation","enrollment":475},{"nctId":"NCT00384137","phase":"PHASE3","title":"A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-10","conditions":"Transplantation","enrollment":128},{"nctId":"NCT00064701","phase":"PHASE3","title":"Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-06","conditions":"Kidney Transplantation","enrollment":668},{"nctId":"NCT00282256","phase":"PHASE2","title":"A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-01","conditions":"Liver Transplantation","enrollment":19},{"nctId":"NCT00282243","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-02","conditions":"Liver Transplantation","enrollment":70},{"nctId":"NCT00282568","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-08","conditions":"Kidney Transplantation","enrollment":70},{"nctId":"NCT01092299","phase":"PHASE1","title":"A Bioavailability Study Comparing Modified-release Capsules and Immediate Release Capsules in Fed and Fasting Conditions","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-02","conditions":"Healthy","enrollment":62},{"nctId":"NCT00909571","phase":"PHASE3","title":"Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04","conditions":"Liver Transplantation","enrollment":10},{"nctId":"NCT00988624","phase":"PHASE1","title":"A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-10","conditions":"Alzheimer's Disease, Huntington Disease","enrollment":20},{"nctId":"NCT00720408","phase":"PHASE3","title":"A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-12","conditions":"Liver Transplantation, Transplantation Immunology, Host vs Graft Reaction","enrollment":48},{"nctId":"NCT00719745","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-02","conditions":"Liver Transplantation","enrollment":74},{"nctId":"NCT00720265","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-02","conditions":"Kidney Transplantation","enrollment":135},{"nctId":"NCT00189748","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-08","conditions":"Bone Marrow Transplantation, Graft Versus Host Disease, Graft-Versus-Host Disease","enrollment":""},{"nctId":"NCT00189761","phase":"PHASE2","title":"A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"","conditions":"Bone Marrow Transplantation, Graft Versus Host Disease, Graft-Vs-Host Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"TRANSPLANT REJECTION"},{"count":5,"reaction":"PYREXIA"},{"count":4,"reaction":"CATHETER REMOVAL"},{"count":4,"reaction":"PNEUMONIA"},{"count":4,"reaction":"PULMONARY EMBOLISM"},{"count":4,"reaction":"SEPSIS"},{"count":3,"reaction":"ACUTE KIDNEY INJURY"},{"count":3,"reaction":"RENAL IMPAIRMENT"},{"count":3,"reaction":"TRANSPLANT FAILURE"},{"count":3,"reaction":"URINARY TRACT INFECTION"}],"_approvalHistory":[],"publicationCount":419,"recentPublications":[{"date":"2026 Mar 16","pmid":"41898572","title":"Activated Memory Cytotoxic T-Lymphocytes and T-Cell Receptor Vβ Clonality Predict Treatment-Free Remission After Tyrosine Kinase Inhibitor Discontinuation in Chronic-Phase Chronic Myeloid Leukemia: A 1-Year Prospective Immuno-Monitoring Study.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 3","pmid":"41876352","title":"Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis.","journal":"Clinical lymphoma, myeloma & leukemia"},{"date":"2026 Mar 8","pmid":"41797306","title":"Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.","journal":"British journal of haematology"},{"date":"2026","pmid":"41780960","title":"[How I manage chronic myeloid leukemia patients' fertility].","journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology"},{"date":"2026 Feb 11","pmid":"41668074","title":"Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.","journal":"BMC cancer"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Modified Release Tacrolimus","FK506MR","FK506E"],"phase":"phase_3","status":"active","brandName":"MR4","genericName":"MR4","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}